Related resources
Full-text held externally
- PMID: 23369683
- UKPMCID: 23369683
- DOI: 10.1016/S1470-2045(12)70553-3
Search for item elsewhere
University researcher(s)
Academic department(s)
Pathobiology of chemotherapy-induced hair loss.
Paus, Ralf; Haslam, Iain S; Sharov, Andrey A; Botchkarev, Vladimir A
The lancet oncology. 2013;14(2):e50-9.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 23369683
- UKPMCID: 23369683
- DOI: 10.1016/S1470-2045(12)70553-3
Abstract
Hair loss can be a psychologically devastating adverse effect of chemotherapy, but satisfactory management strategies for chemotherapy-induced alopecia remain elusive. In this Review we focus on the complex pathobiology of this side-effect. We discuss the clinical features and current management approaches, then draw upon evidence from mouse models and human hair-follicle organ-culture studies to explore the main pathobiology principles and explain why chemotherapy-induced alopecia is so challenging to manage. P53-dependent apoptosis of hair-matrix keratinocytes and chemotherapy-induced hair-cycle abnormalities, driven by the dystrophic anagen or dystrophic catagen pathway, play important parts in the degree of hair-follicle damage, alopecia phenotype, and hair-regrowth pattern. Additionally, the degree of hair-follicle stem-cell damage determines whether chemotherapy-induced alopecia is reversible. We highlight the need for carefully designed preclinical research models to generate novel, clinically relevant pointers to how this condition may be overcome.